CGEM vs MYE Comparison

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Myers Industries Inc designs, manufactures, and markets a variety of plastic, metal, and rubber products, including a broad selection of plastic reusable containers, pallets, small parts bins, bulk shipping containers, storage and organization products, OEM parts, custom plastic products, consumer fuel containers and tanks for water, fuel and waste handling. It operates through the following segments: The Material Handling segment manufactures a selection of durable plastic reusable products that are used repeatedly during the course of their service life. The Distribution segment is engaged in the distribution of equipment, tools, and supplies used for tire servicing and automotive under-vehicle repair, etc. It generates the majority of its revenue from the Material Handling segment.